Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
The inhibition of the mitogen-activated protein kinases signalling pathway through combined use of BRAF and MEK inhibitors (BRAFi+MEKi) represents an established therapeutic option in patients with BRAF-mutated, advanced melanoma. These efficient therapies are well tolerated with mostly moderate and...
| Auteurs principaux: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
Elsevier
2019-06-01
|
| Collection: | ESMO Open |
| Accès en ligne: | https://esmoopen.bmj.com/content/4/3/e000491.full |